Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy

Status: Completed
Location: See all (11) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This study aims to evaluate the feasibility, acceptability, and effectiveness of dispensing mifepristone via a mail-order pharmacy. The investigators will recruit patients at up to 10 primary care and internal medicines sites not currently providing abortion services around the country, as well as abortion clinic sites. Patients will go through routine in clinic visits to determine eligibility and then will receive the medications in the mail at their preferred address. The investigators will survey patients 3 and 14 days after the initial clinic visit and interview providers at the end of the study.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 15
Healthy Volunteers: t
View:

• Women seeking medication abortion through 63 days gestation

• Eligible for MifeprexⓇ at a study site

• English or Spanish speaking

• Willing and able to participate in the study, including willing and able to receive medications at home or other preferred address within 3 days of initial medication abortion visit

Locations
United States
California
Children's Hospital Oakland
Oakland
Highland Hospital
Oakland
Colorado
Planned Parenthood Rocky Mountains
Denver
Delaware
Christiana Care Health System
Wilmington
Georgia
Atlanta Comprehensive Wellness Clinic
Atlanta
New York
Albert Einstein College of Medicine
New York
Southern Tier Women's Health Services
Vestal
Pennsylvania
Delaware County Women's Center
Chester
Allegheny Reproductive Health Center
Pittsburgh
Rhode Island
Brown Family Medicine
Pawtucket
Lifespan
Providence
Time Frame
Start Date: 2020-01-05
Completion Date: 2023-07-30
Participants
Target number of participants: 536
Treatments
Experimental: Medication Abortion Patients
Oral Mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone)
Sponsors
Leads: Daniel Grossman, MD

This content was sourced from clinicaltrials.gov